Jan Pfeiffenberger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665504/publications.pdf

Version: 2024-02-01

623734 610901 32 634 14 24 g-index citations h-index papers 33 33 33 949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3163-3174.	2.5	3
2	Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2471-2481.	2.5	6
3	SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study. Transplantation Proceedings, 2021, 53, 1112-1117.	0.6	11
4	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). Journal of Hepatology, 2021, 75, 1346-1354.	3.7	69
5	Biliary Rhabdomyosarcoma in Pediatric Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. Frontiers in Oncology, 2021, 11, 701400.	2.8	8
6	Optimized Trientineâ€dihydrochloride Therapy in Pediatric Patients With Wilson Disease. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 115-122.	1.8	6
7	Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1269-1279.	3.7	4
8	Nonâ€invasive diagnosis of cirrhosis and longâ€term disease monitoring by transient elastography in patients with Wilson disease. Liver International, 2020, 40, 894-904.	3.9	19
9	The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. Orphanet Journal of Rare Diseases, 2020, 15, 173.	2.7	6
10	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1033-1050.	2.5	14
11	Coagulation Parameters in Wilson Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 183-188.	0.9	5
12	Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2761-2769.	2.5	7
13	Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World Journal of Gastroenterology, 2019, 25, 1603-1617.	3.3	18
14	Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 1692.	2.4	11
15	Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS ONE, 2019, 14, e0222771.	2.5	25
16	Longâ€term evaluation of urinary copper excretion and nonâ€caeruloplasmin associated copper in Wilson disease patients under medical treatment. Journal of Inherited Metabolic Disease, 2019, 42, 371-380.	3.6	23
17	Case report: a rare cause of a hypervascular nodule in a noncirrhotic liver. Zeitschrift Fur Gastroenterologie, 2019, 57, 57-60.	0.5	4
18	Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. British Journal of Cancer, 2019, 120, 109-114.	6.4	71

#	Article	IF	CITATIONS
19	Multidrug-Resistant Bacteria and Disease Progression in Patients with End-Stage Liver Disease and after Liver Transplantation. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 303-310.	0.9	8
20	Routine Liver Elastography Could Predict Actuarial Survival after Liver Transplantation. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 271-277.	0.9	5
21	The steady state pharmacokinetics of trientine in Wilson disease patients. European Journal of Clinical Pharmacology, 2018, 74, 731-736.	1.9	7
22	Pregnancy in Wilson's disease: Management and outcome. Hepatology, 2018, 67, 1261-1269.	7.3	61
23	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Gastrointestinal Tumors, 2018, 5, 38-46.	0.7	8
24	The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation. Langenbeck's Archives of Surgery, 2018, 403, 719-731.	1.9	31
25	Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World Journal of Gastroenterology, 2018, 24, 1353-1360.	3.3	7
26	Comparative assessment of clinical rating scales in Wilson's disease. BMC Neurology, 2017, 17, 140.	1.8	28
27	Wilson disease: Health-related quality of life and risk for depression. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 349-356.	1.5	21
28	Concomitant immuneâ€related events in Wilson disease: implications for monitoring chelator therapy. Journal of Inherited Metabolic Disease, 2016, 39, 125-130.	3.6	15
29	Hepatobiliary malignancies in Wilson disease. Liver International, 2015, 35, 1615-1622.	3.9	78
30	Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbeck's Archives of Surgery, 2013, 398, 1123-1128.	1.9	17
31	Factors modifying phenotypic presentation in Wilson disease: authors' reply. Liver International, 2012, 32, 870-870.	3.9	0
32	Iron metabolism and the role of <scp>HFE</scp> gene polymorphisms in <scp>W</scp> ilson disease. Liver International, 2012, 32, 165-170.	3.9	38